{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:15:59Z","timestamp":1795025759013,"version":"4.10.2"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-64172-w","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T09:45:05Z","timestamp":1760521505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Dendritic cell progenitors engineered to express extracellular-vesicle\u2013internalizing receptors enhance cancer immunotherapy in mouse models"],"prefix":"10.1038","volume":"16","author":[{"given":"Ali","family":"Ghasemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3416-1529","authenticated-orcid":false,"given":"Amaia","family":"Martinez-Usatorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadrien","family":"Demagny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Mohammadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hicham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7848-9377","authenticated-orcid":false,"given":"Colin E. J.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2031-3250","authenticated-orcid":false,"given":"Daniel E.","family":"Speiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0151-3222","authenticated-orcid":false,"given":"Denis","family":"Migliorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9128-5459","authenticated-orcid":false,"given":"Michele","family":"De Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"64172_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13368-y","volume":"10","author":"CR Perez","year":"2019","unstructured":"Perez, C. R. & De Palma, M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat. Commun. 10, 5408 (2019).","journal-title":"Nat. Commun."},{"key":"64172_CR2","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.immuni.2023.08.014","volume":"56","author":"MJ Pittet","year":"2023","unstructured":"Pittet, M. J., Di Pilato, M., Garris, C. & Mempel, T. R. Dendritic cells as shepherds of T cell immunity in cancer. Immunity 56, 2218\u20132230 (2023).","journal-title":"Immunity"},{"key":"64172_CR3","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200264","volume":"218","author":"GM Gerhard","year":"2021","unstructured":"Gerhard, G. M., Bill, R., Messemaker, M., Klein, A. M. & Pittet, M. J. Tumor-infiltrating dendritic cell states are conserved across solid human cancers. J. Exp. Med. 218, e20200264 (2021).","journal-title":"J. Exp. Med."},{"key":"64172_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-immunol-061020-053707","volume":"39","author":"M Cabeza-Cabrerizo","year":"2021","unstructured":"Cabeza-Cabrerizo, M., Cardoso, A., Minutti, C. M., Pereira da Costa, M. & Reis e Sousa, C. Dendritic cells revisited. Annu. Rev. Immunol. 39, 131\u2013166 (2021).","journal-title":"Annu. Rev. Immunol."},{"key":"64172_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete, A. et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell. Mol. Immunol. 20, 432\u2013447 (2023).","journal-title":"Cell. Mol. Immunol."},{"key":"64172_CR6","doi-asserted-by":"publisher","first-page":"101481","DOI":"10.1016\/j.smim.2021.101481","volume":"52","author":"AE Marciscano","year":"2021","unstructured":"Marciscano, A. E. & Anandasabapathy, N. The role of dendritic cells in cancer and anti-tumor immunity. Semin. Immunol. 52, 101481 (2021).","journal-title":"Semin. Immunol."},{"key":"64172_CR7","doi-asserted-by":"publisher","first-page":"eadf4726","DOI":"10.1126\/sciimmunol.adf4726","volume":"10","author":"V Bhandarkar","year":"2025","unstructured":"Bhandarkar, V., Dinter, T. & Spranger, S. Architects of immunity: how dendritic cells shape CD8+ T cell fate in cancer. Sci. Immunol. 10, eadf4726 (2025).","journal-title":"Sci. Immunol."},{"key":"64172_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nm0196-52","volume":"2","author":"FJ Hsu","year":"1996","unstructured":"Hsu, F. J. et al. Vaccination of patients with B\u2013cell lymphoma using autologous antigen\u2013pulsed dendritic cells. Nat. Med. 2, 52\u201358 (1996).","journal-title":"Nat. Med."},{"key":"64172_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","volume":"11","author":"J Yu","year":"2022","unstructured":"Yu, J., Sun, H., Cao, W., Song, Y. & Jiang, Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp. Hematol. Oncol. 11, 3 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"64172_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","volume":"21","author":"I Heras-Murillo","year":"2024","unstructured":"Heras-Murillo, I., Ad\u00e1n-Barrientos, I., Gal\u00e1n, M., Wculek, S. K. & Sancho, D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat. Rev. Clin. Oncol. 21, 257\u2013277 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"64172_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41573-020-0074-8","volume":"19","author":"A Harari","year":"2020","unstructured":"Harari, A., Graciotti, M., Bassani-Sternberg, M. & Kandalaft, L. E. Antitumour dendritic cell vaccination in a priming and boosting approach. Nat. Rev. Drug Discov. 19, 635\u2013652 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64172_CR12","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","volume":"15","author":"S Anguille","year":"2014","unstructured":"Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F. & Berneman, Z. N. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 15, e257\u2013e267 (2014).","journal-title":"Lancet Oncol."},{"key":"64172_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"64172_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"64172_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12197","volume":"11","author":"N Leary","year":"2022","unstructured":"Leary, N. et al. Melanoma-derived extracellular vesicles mediate lymphatic remodelling and impair tumour immunity in draining lymph nodes. J. Extracell. Vesicles 11, e12197 (2022).","journal-title":"J. Extracell. Vesicles"},{"key":"64172_CR16","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3389\/fphar.2019.01152","volume":"10","author":"O Markov","year":"2019","unstructured":"Markov, O., Oshchepkova, A. & Mironova, N. Immunotherapy based on dendritic cell-targeted\/-derived extracellular vesicles-a novel strategy for enhancement of the anti-tumor immune response. Front. Pharmacol. 10, 1152 (2019).","journal-title":"Front. Pharmacol."},{"key":"64172_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-27604-5","volume":"13","author":"VM Ukrainskaya","year":"2023","unstructured":"Ukrainskaya, V. M. et al. CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality. Sci. Rep. 13, 463 (2023).","journal-title":"Sci. Rep."},{"key":"64172_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/85438","volume":"7","author":"J Wolfers","year":"2001","unstructured":"Wolfers, J. et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 7, 297\u2013303 (2001).","journal-title":"Nat. Med."},{"key":"64172_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nmeth.4579","volume":"15","author":"ML Squadrito","year":"2018","unstructured":"Squadrito, M. L., Cianciaruso, C., Hansen, S. K. & De Palma, M. EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens. Nat. Methods 15, 183\u2013186 (2018).","journal-title":"Nat. Methods"},{"key":"64172_CR20","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","volume":"10","author":"B Nazha","year":"2020","unstructured":"Nazha, B., Inal, C. & Owonikoko, T. K. Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front. Oncol. 10, 1000 (2020).","journal-title":"Front. Oncol."},{"key":"64172_CR21","doi-asserted-by":"crossref","unstructured":"MacNabb, B. W. & Kline, J. MHC cross-dressing in antigen presentation. Adv. Immunol. 159, 115\u2013147 (2023).","DOI":"10.1016\/bs.ai.2023.07.001"},{"key":"64172_CR22","doi-asserted-by":"publisher","first-page":"e16523","DOI":"10.15252\/emmm.202216523","volume":"14","author":"A Martinez-Usatorre","year":"2022","unstructured":"Martinez-Usatorre, A. & De Palma, M. Dendritic cell cross-dressing and tumor immunity. EMBO Mol. Med. 14, e16523 (2022).","journal-title":"EMBO Mol. Med."},{"key":"64172_CR23","doi-asserted-by":"publisher","first-page":"101710","DOI":"10.1016\/j.smim.2023.101710","volume":"66","author":"F Chatterjee","year":"2023","unstructured":"Chatterjee, F. & Spranger, S. MHC-dressing on dendritic cells: Boosting anti-tumor immunity via unconventional tumor antigen presentation. Semin. Immunol. 66, 101710 (2023).","journal-title":"Semin. Immunol."},{"key":"64172_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s43018-023-00668-y","volume":"5","author":"A Ghasemi","year":"2024","unstructured":"Ghasemi, A. et al. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy. Nat. Cancer 5, 240\u2013261 (2024).","journal-title":"Nat. Cancer"},{"key":"64172_CR25","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon, H. et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924\u2013938 (2016).","journal-title":"Immunity"},{"key":"64172_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723.e4 (2017).","journal-title":"Cancer Cell"},{"key":"64172_CR27","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1182\/blood-2013-12-545772","volume":"124","author":"CT Mayer","year":"2014","unstructured":"Mayer, C. T. et al. Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow. Blood 124, 3081\u20133091 (2014).","journal-title":"Blood"},{"key":"64172_CR28","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.3390\/cancers14081976","volume":"14","author":"Y Saito","year":"2022","unstructured":"Saito, Y., Komori, S., Kotani, T., Murata, Y. & Matozaki, T. The role of type-2 conventional dendritic cells in the regulation of tumor immunity. Cancers 14, 1976 (2022).","journal-title":"Cancers"},{"key":"64172_CR29","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cell.2019.02.005","volume":"177","author":"M Binnewies","year":"2019","unstructured":"Binnewies, M. et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity. Cell 177, 556\u2013571.e16 (2019).","journal-title":"Cell"},{"key":"64172_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-04941-5","volume":"12","author":"L Lu","year":"2022","unstructured":"Lu, L. et al. Differential expression of CD11c defines two types of tissue-resident macrophages with different origins in steady-state salivary glands. Sci. Rep. 12, 931 (2022).","journal-title":"Sci. Rep."},{"key":"64172_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay3575","volume":"12","author":"DM Francis","year":"2020","unstructured":"Francis, D. M. et al. Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Sci. Transl. Med. 12, eaay3575 (2020).","journal-title":"Sci. Transl. Med."},{"key":"64172_CR32","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12. Immunity 49, 1148\u20131161.e7 (2018).","journal-title":"Immunity"},{"key":"64172_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112498","volume":"28","author":"F Duval","year":"2025","unstructured":"Duval, F. et al. Trajectories of macrophage ontogeny and reprogramming in cancer. iScience 28, 112498 (2025).","journal-title":"iScience"},{"key":"64172_CR34","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.4049\/jimmunol.171.11.5787","volume":"171","author":"MP Piechocki","year":"2003","unstructured":"Piechocki, M. P., Ho, Y.-S., Pilon, S. & Wei, W.-Z. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J. Immunol. 171, 5787\u20135794 (2003).","journal-title":"J. Immunol."},{"key":"64172_CR35","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/sj.gt.3301433","volume":"8","author":"SS Diebold","year":"2001","unstructured":"Diebold, S. S., Cotten, M., Koch, N. & Zenke, M. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther. 8, 487\u2013493 (2001).","journal-title":"Gene Ther."},{"key":"64172_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0092-8674(94)90169-4","volume":"76","author":"KA Hogquist","year":"1994","unstructured":"Hogquist, K. A. et al. T cell receptor antagonist peptides induce positive selection. Cell 76, 17\u201327 (1994).","journal-title":"Cell"},{"key":"64172_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1046\/j.1440-1711.1998.00709.x","volume":"76","author":"MJ Barnden","year":"1998","unstructured":"Barnden, M. J., Allison, J., Heath, W. R. & Carbone, F. R. Defective TCR expression in transgenic mice constructed using cDNA-based \u03b1- and \u03b2-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76, 34\u201340 (1998).","journal-title":"Immunol. Cell Biol."},{"key":"64172_CR38","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1158\/0008-5472.CAN-16-2680","volume":"77","author":"NJ Neubert","year":"2017","unstructured":"Neubert, N. J. et al. Broad and conserved immune regulation by genetically heterogeneous melanoma cells. Cancer Res. 77, 1623\u20131636 (2017).","journal-title":"Cancer Res."},{"key":"64172_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan3311","volume":"10","author":"NJ Neubert","year":"2018","unstructured":"Neubert, N. J. et al. T cell\u2013induced CSF1 promotes melanoma resistance to PD1 blockade. Sci. Transl. Med. 10, eaan3311 (2018).","journal-title":"Sci. Transl. Med."},{"key":"64172_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4049\/jimmunol.0803647","volume":"183","author":"EM Iancu","year":"2009","unstructured":"Iancu, E. M. et al. Clonotype selection and composition of human cd8 t cells specific for persistent herpes viruses varies with differentiation but is stable over time1. J. Immunol. 183, 319\u2013331 (2009).","journal-title":"J. Immunol."},{"key":"64172_CR41","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638\u2013652 (2014).","journal-title":"Cancer Cell"},{"key":"64172_CR42","doi-asserted-by":"publisher","first-page":"e003571","DOI":"10.1136\/jitc-2021-003571","volume":"10","author":"A Gardner","year":"2022","unstructured":"Gardner, A. et al. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8+ T cell and XCR1+ dendritic cell spatial co-localization. J. Immunother. Cancer 10, e003571 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"64172_CR43","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s43018-021-00241-5","volume":"2","author":"MC Milone","year":"2021","unstructured":"Milone, M. C. et al. Engineering-enhanced CAR T cells for improved cancer therapy. Nat. Cancer 2, 780\u2013793 (2021).","journal-title":"Nat. Cancer"},{"key":"64172_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46685-y","volume":"15","author":"L L\u00f3pez","year":"2024","unstructured":"L\u00f3pez, L. et al. Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors. Nat. Commun. 15, 2280 (2024).","journal-title":"Nat. Commun."},{"key":"64172_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2326-6066.CIR-21-0326","volume":"10","author":"C Pfirschke","year":"2022","unstructured":"Pfirschke, C. et al. Macrophage-targeted therapy unlocks antitumoral cross-talk between IFN\u03b3-secreting lymphocytes and IL12-producing dendritic cells. Cancer Immunol. Res. 10, 40\u201355 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"64172_CR46","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","volume":"26","author":"B Ruffell","year":"2014","unstructured":"Ruffell, B. et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26, 623\u2013637 (2014).","journal-title":"Cancer Cell"},{"key":"64172_CR47","doi-asserted-by":"publisher","first-page":"135143","DOI":"10.1172\/jci.insight.135143","volume":"5","author":"D Ashour","year":"2020","unstructured":"Ashour, D. et al. IL-12 from endogenous cDC1, and not vaccine DC, is required for Th1 induction. JCI Insight 5, 135143 e135143. (2020).","journal-title":"JCI Insight"},{"key":"64172_CR48","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","volume":"25","author":"L Hammerich","year":"2019","unstructured":"Hammerich, L. et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat. Med. 25, 814\u2013824 (2019).","journal-title":"Nat. Med."},{"key":"64172_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00537-x","volume":"11","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo, K., Taremi, S., Heidari, M. & Esmaeilzadeh, A. The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors. Biomark. Res. 11, 103 (2023).","journal-title":"Biomark. Res."},{"key":"64172_CR50","doi-asserted-by":"publisher","first-page":"1291619","DOI":"10.3389\/fimmu.2023.1291619","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang, Y., Xu, Q. & Gao, Q. Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils. Front. Immunol. 14, 1291619 (2023).","journal-title":"Front. Immunol."},{"key":"64172_CR51","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/0008-5472.CAN-20-2990","volume":"81","author":"NR Anderson","year":"2021","unstructured":"Anderson, N. R., Minutolo, N. G., Gill, S. & Klichinsky, M. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 81, 1201\u20131208 (2021).","journal-title":"Cancer Res."},{"key":"64172_CR52","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"64172_CR53","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.3390\/cells11223692","volume":"11","author":"M Liu","year":"2022","unstructured":"Liu, M. et al. CAR-Macrophages and CAR-T cells synergistically kill tumor cells in vitro. Cells 11, 3692 (2022).","journal-title":"Cells"},{"key":"64172_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55770-1","volume":"16","author":"S Pierini","year":"2025","unstructured":"Pierini, S. et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models. Nat. Commun. 16, 706 (2025).","journal-title":"Nat. Commun."},{"key":"64172_CR55","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss, K. A. et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat. Med. 31, 1171\u20131182 (2025).","journal-title":"Nat. Med."},{"key":"64172_CR56","doi-asserted-by":"crossref","unstructured":"Majumder, A. et al. Generation of GD2-CAR neutrophils from hPSCs for targeted cancer immunotherapy of solid tumors. J. Immunother. Cancer 10, (2022).","DOI":"10.1136\/jitc-2022-SITC2022.0356"},{"key":"64172_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37872-4","volume":"14","author":"Y Chang","year":"2023","unstructured":"Chang, Y. et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat. Commun. 14, 2266 (2023).","journal-title":"Nat. Commun."},{"key":"64172_CR58","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"64172_CR59","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13287-024-03810-4","volume":"15","author":"N Tsuneyoshi","year":"2024","unstructured":"Tsuneyoshi, N. et al. Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity. Stem Cell Res. Ther. 15, 193 (2024).","journal-title":"Stem Cell Res. Ther."},{"key":"64172_CR60","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nm871","volume":"9","author":"M De Palma","year":"2003","unstructured":"De Palma, M., Venneri, M. A., Roca, C. & Naldini, L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 9, 789\u2013795 (2003).","journal-title":"Nat. Med."},{"key":"64172_CR61","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0076-6879(02)46074-0","volume":"346","author":"M De Palma","year":"2002","unstructured":"De Palma, M. & Naldini, L. Transduction of a gene expression cassette using advanced generation lentiviral vectors. Methods Enzymol. 346, 514\u2013529 (2002).","journal-title":"Methods Enzymol."},{"key":"64172_CR62","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/0092-8674(92)90030-G","volume":"68","author":"P Mombaerts","year":"1992","unstructured":"Mombaerts, P. et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869\u2013877 (1992).","journal-title":"Cell"},{"key":"64172_CR63","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/emmm.201303297","volume":"6","author":"IJ Huijbers","year":"2014","unstructured":"Huijbers, I. J. et al. Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol. Med. 6, 212\u2013225 (2014).","journal-title":"EMBO Mol. Med."},{"key":"64172_CR64","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.immuni.2007.03.016","volume":"26","author":"Peter Stranges","year":"2007","unstructured":"Stranges, P. et al. Fas-mediated elimination of antigen-presenting cells and autoreactive T cells contribute to prevention of autoimmunity. Immunity 26, 629\u2013641 (2007).","journal-title":"Immunity"},{"key":"64172_CR65","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.immuni.2015.05.018","volume":"42","author":"J Helft","year":"2015","unstructured":"Helft, J. et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells. Immunity 42, 1197\u20131211 (2015).","journal-title":"Immunity"},{"key":"64172_CR66","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nprot.2011.327","volume":"6","author":"G Berger","year":"2011","unstructured":"Berger, G. et al. A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1\u2013derived lentiviral vectors. Nat. Protoc. 6, 806\u2013816 (2011).","journal-title":"Nat. Protoc."},{"key":"64172_CR67","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/gt.2012.61","volume":"20","author":"S Bobadilla","year":"2013","unstructured":"Bobadilla, S., Sunseri, N. & Landau, N. R. Efficient transduction of myeloid cells by a lentiviral vector that packages the Vpx accessory protein. Gene Ther. 20, 514\u2013520 (2013).","journal-title":"Gene Ther."},{"key":"64172_CR68","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1016\/j.celrep.2019.05.008","volume":"27","author":"C Cianciaruso","year":"2019","unstructured":"Cianciaruso, C. et al. Molecular profiling and functional analysis of macrophage-derived tumor extracellular vesicles. Cell Rep. 27, 3062\u20133080.e11 (2019).","journal-title":"Cell Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64172-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64172-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64172-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:08:30Z","timestamp":1760526510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64172-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64172"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64172-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.D.P. has received sponsored research grants from EVIR Therapeutics, Hoffmann La-Roche and Deciphera Pharmaceuticals, serves on the Scientific Advisory Boards of EVIR Therapeutics, Montis Biosciences, Macomics, Deciphera Pharmaceuticals, Light Chain Bioscience\/Novimmune, and Genenta. M.D.P., A.G., Y.M. and A.M.-U. are inventors on patents WO\/2017\/134100, WO\/2023\/232777, and application No. 24211693.7 filed by EPFL, which cover methods for DC engineering. D.E.S. serves on the Scientific Advisory Board of EVIR Therapeutics. D.M. is a consultant for Limula and MPC Therapeutics, scientific co-founder of Cellula Therapeutics, and inventor on unrelated patents filed by the University of Pennsylvania, Istituto Oncologico della Svizzera Italiana (IOSI) and the University of Geneva. The other authors declare no Competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9148"}}